Prot #M12-555: A Phase 3 Open-Label Study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to Severe Hidradenitis Suppurativa – PIONEER (OPEN-LABEL EXTENSION)

    Project: Research project

    Project Details

    StatusFinished
    Effective start/end date12/10/1312/10/19

    Funding

    • AbbVie Inc. (Prot #M12-555)